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A B S T R A C T   
Background: There is a lack of information about the burden of metastatic castration-resistant prostate cancer 
(mCRPC). The present work aims to estimate the incidence and prevalence of mCRPC in 2014 using the French 
nationwide healthcare database (SNDS). 
Methods: Prevalence and incidence were estimated based on an SNDS extraction of men covered by the general 
healthcare insurance (86 % of the French population), and aged ≥40. Patients with mCRPC were identified 
amongst prostate cancer cases using an algorithm estimating a date of first metastasis management and a date of 
castration resistance. This algorithm was validated by clinical experts through a blind review of 200 anonymized 
medical charts from SNDS data. Prevalence and incidence were standardized on the European Standard Popu-
lation (2013 edition). 
Results: Prevalence and incidence of mCRPC were estimated as, respectively, 62 and 21 cases per 100 000 men in 
2014. Less than one mCRPC case per 100 000 was observed in men aged 40–49. Maximum mCRPC incidence was 
in men aged 80–89 (175 per 100 000). The algorithm used for mCRPC identification had 97 % positive and 99 % 
negative predictive values. 
Conclusion: The good performances of the algorithm for mCRPC identification and the consistency of the 
generated results with the existing data highlight the robustness of these first estimates of mCRPC prevalence and 
incidence. Future updates will call for algorithm adjustment as practices evolve over time. These first real-life 
data will serve for future follow-up of the impact of changes in the management of prostate cancer.   
1. Introduction 
Prostate cancer (PC) is the most common cancer in men [1]. The 
management of PC depends on the stage of the disease. Locally limited 
disease usually receives active surveillance or local treatment such as 
surgery, radiotherapy, brachytherapy, or high-intensity focused 
ultrasound (HIFU) [2–5]. In advanced PC, androgen deprivation therapy 
(ADT)—relying on gonadotropin-releasing hormone (GnRH) analogs or 
antagonists, anti-androgens or estrogens—is added to the local treat-
ment [2–5]. However, after varying lengths of time, many patients 
develop resistance to ADT (castration-resistant PC, CRPC) [6]. Patients 
diagnosed at localized and locally advanced stages develop metastases 
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E-mail address: nicolas.thurin@u-bordeaux.fr (N.H. Thurin).  
Contents lists available at ScienceDirect 
Cancer Epidemiology 
journal homepage: www.elsevier.com/locate/canep 
https://doi.org/10.1016/j.canep.2020.101833 
Received 4 June 2020; Received in revised form 7 September 2020; Accepted 25 September 2020   
Cancer Epidemiology 69 (2020) 101833
2
within 5 years in 20 % and 40 % of cases respectively [7]. Thus, patients 
progress gradually from non-metastatic hormone-sensitive PC to meta-
static castration-resistant PC (mCRPC), requiring specific treatments 
such as androgen-receptor-targeted therapies (abiraterone acetate or 
enzalutamide) or chemotherapy (docetaxel, cabazitaxel), most of the 
time with prednisone or prednisolone [3,8,9]. 
The French National Cancer Institute (Institut National du Cancer, 
INCa) and the French Network of Cancer Registries (Francim) estimated 
the total prevalence of PC in 2008 in France at 508 699, with 53 913 new 
cases in 2011 and 50 430 cases in 2015 [1,10,11]. Many studies have 
been limited to local registries, estimating national incidences using 
mortality as a correlate [10,12]. More recent estimations can be found in 
studies that used the French nationwide healthcare database (Système 
National des Données de Santé, SNDS) [13,14]. However, no data are 
available on metastatic, resistant or mCRPC stages. The CAMERRA 
study—TherapeutiC strAtegy in MEtastatic castration-Resistant pRos-
tate cAncer: target population and changes between 2012 and 
2014—was launched to address the lack of real-world data about this 
specific stage of PC, identifying mCRPC patient in the SNDS database, 
describing their characteristics, and assessing the evolution of their 
management. The objective of this paper is to introduce and discuss the 
first stage of the study, the identification of the mCRPC patients 
(including the estimation of the mCRPC incidence and prevalence in 
2014), to provide rational for forthcoming CAMERRA results. 
2. Methods 
2.1. Study design 
The incidence and prevalence of PC and mCRPC were estimated for 
the year 2014 through a cross-sectional study using the SNDS database 
over the period 2009–2014. Access to data was approved by the national 
data protection agency (CNIL) after the review of the protocol by a 
specific committee in health data research (CEREES) [15]. 
2.2. Data source 
The SNDS covers almost the whole French population (98.8 %) from 
birth (or immigration) to death (or emigration) [16]. Captured data 
include (among others): (a) gender, year of birth, location, date of death, 
(b) outpatient reimbursed healthcare expenditures such as medical 
visits, laboratory tests (without results), drugs dispensed with date and 
quantity supplied (but not the indication), etc., (c) inpatient hospital 
discharge summaries with medical and imaging procedures performed, 
International Classification of Diseases (ICD10) codes for diagnoses, etc., 
and (d) registration for long-term diseases (affections de longue durée in 
French) allowing the full coverage of the expenses related to the regis-
tered disease, including ICD10 codes (C61 for PC). 
2.3. Study population 
To be included, men had to be alive on January 1st 2014, aged ≥40 
years, and with no gap >1 year in their data history. This threshold was 
chosen because PC is extremely rare in men under 40 [11]. In addition, 
to join the study population, men also had to be covered by the general 
health insurance scheme—corresponding to 86 % of the French pop-
ulation—because until 2010 not all the specific French insurance 
schemes (independent professions, farmers, etc.) were loading their 
whole data into the SNDS. 
2.4. Identification of PC 
Patients with PC were identified in the study population by the 
presence of at least one of the following criteria in 2014: (a) registration 
for PC as a long-term disease declared prior to December 31st 2014, (b) 
reimbursements for drugs corresponding to at least 2 months of ADT, (c) 
at least one reimbursement of estramustine or mCRPC-specific treat-
ments (abiraterone acetate, enzalutamide or cabazitaxel), and (d) a 
hospital stay for PC, including notably chemotherapy (docetaxel) or 
radiotherapy, and a PC-specific procedure or treatment observed in the 
5-year history period (e.g. radical prostatectomy, orchiectomy, HIFU, 
brachytherapy, cryotherapy). In order to be more specific, patients 
presumed chemically castrated for a reason other than PC, especially 
paraphilia, were excluded (see Supplementary data, Appendix A). For 
the remaining patients, a date of diagnosis was estimated using the first 
PC-specific event recorded. 
2.5. Identification of mCRPC 
To be considered as having mCRPC, a patient with PC had to com-
plete two conditions: to be identified as both metastatic and castration- 
resistant. The construction of these two complex indicators relies on 
several proxies, which have been developed by a multidisciplinary team 
composed of oncologists, urologists, radiation therapists, pharmacists 
and epidemiologists. 
2.5.1. Estimation of the date of first metastasis management 
The first hospital stay with ICD10 discharge diagnosis code for 
‘secondary malignant neoplasm’ (C77, C78, C79) was used to set the first 
metastasis diagnosis date for patients with PC, if no other cancer was 
mentioned in the diagnosis. Denosumab or zoledronic acid dispensing 
(excluding Aclasta®) as well as targeted β or α particle therapy and 
hepatic radiofrequency ablations were also used to estimate the date of 
metastases. Dispensings of specific mCRPC treatment, including doce-
taxel (see Supplementary data, Appendix B), were considered as 
metastasis indicators if preceded by a medical imaging procedure and at 
least 3 months of continuous ADT. In the particular case of the youngest 
patients (<70 years old) who directly started ADT after PC diagnosis 
until the dispensing of an mCRPC-specific treatment without any pre-
vious local treatment, the first metastasis diagnosis date corresponded to 
the first GnRH analog dispensing unless the patient died in the first ADT 
year. The last way used to identify the date of metastases was through 
radiotherapy (see Supplementary data, Appendix C). Three types of 
radiotherapy were distinguished: (a) non-intensity modulated radio-
therapy, (b) intensity-modulated radiotherapy, and (c) stereotactic 
radiotherapy. Duration, number of sessions and previous patient history 
were then used to differentiate between prostate-targeted and 
metastases-targeted radiotherapy. 
Metastases diagnosed within 4 months following the initial PC 
diagnosis were considered as synchronous. 
2.5.2. Estimation of castration resistance diagnosis date 
Detection of castration resistance relies mainly on switching between 
different ADTs. A patient with a GnRH analog or surgical castration 
(orchidectomy, pulpectomy) was considered as resistant to castration at 
the initiation of an anti-androgen, diethylstilbestrol or degarelix for at 
least 2 months. The first dispensing of a CRPC-/mCRPC-specific treat-
ment was also set as a resistance indicator, unless this dispensing took 
place during the first 3 months following the date of diagnosis (hor-
mone-sensitive period). 
2.5.3. mCRPC status 
Patients were classified as prevalent mCRPC when both the date of 
first management of metastases and the date of castration resistance 
were identified in their medical history. The date of mCRPC status was 
set to the most recent of the two previous dates. Incident mCRPC cases 
corresponded to patients for whom mCRPC status was identified in 
2014. 
2.6. Validation of the algorithm 
A validation study was set up in the final stages of the algorithm 
N.H. Thurin et al.                                                                                                                                                                                                                               
Cancer Epidemiology 69 (2020) 101833
3
conception. A sample of 200 patients was randomly created by selecting 
100 mCRPC cases identified by the algorithm and 100 non-mCRPC PC 
cases. So as to ensure the presence of all categories of non-mCRPC pa-
tients, three groups of non-mCRPC patients were identified: 34 with 
non-metastatic hormone-sensitive PC, 33 with metastatic hormone- 
sensitive PC, and 33 with non-metastatic castration-resistant PC. For 
each of these 200 patients a medical chart was reconstituted and ano-
nymized, based on the medical history available in the SNDS during 
2009–2014: long-term disease registration, drug dispensings, procedure 
codes including surgery and imaging, hospitalizations with all diagnosis 
codes, and lab tests (without results). These 200 cases were randomly 
divided into two groups of 100 cases. Two pairs of experts—including a 
urologist and an oncologist—each blindly adjudicated the mCRPC status 
of 100 cases. In case of disagreement within a pair, the case was assessed 
by all four experts to reach consensus. False-negative cases were 
weighed according to the distribution of non-mCRPC patient classes. 
Positive predictive values (PPVs) and negative predictive values (NPVs) 
of the algorithm for mCRPC identification were then calculated. 
Based on expert feedback, following the validation study, slight ad-
justments of indicator settings were implemented in the algorithm. Note 
that the final settings are those described in the present publication. 
PPVs and NPVs were then updated and used to estimate the sensitivity 
and specificity (see Supplementary data, Appendix D) [17]. 
2.7. Analyses 
All analyses were performed using SAS® 9.4 software. Extrapolation 
of the total number of cases in the overall French population was stan-
dardized on the 2014 French age distribution provided by the National 
Institute of Statistics and Economic Studies (Insee) [18]. Extrapolation 
of the incidence and the prevalence per 100 000 men was standardized 
on the 2013 European Standard Population [19]. Given the power of the 
SNDS confidence intervals generated are very narrow and not presented 
here. 
3. Results 
In 2014, among the population of men aged ≥40 covered by the 
general health insurance scheme (86 % of the French population) 386 
127 PC cases were counted (Fig. 1), including 26 470 new ones. Amongst 
the PC population, 28 845 were classified as metastatic and 18 973 as 
castration-resistant (7.5 % and 4.9 % respectively), giving a total of 12 
951 mCRPC patients (3.4 %). By extrapolation, the age-standardized 
prevalence of PC using the European Standard Population was esti-
mated at 1842 per 100 000 men, with an annual incidence of 121 per 
100 000, assuming the rate of PC as negligible for men under the age of 
40. Considering mCRPC, the age-standardized prevalence was 62 cases 
per 100 000 men, with an annual incidence of 21 cases per 100 000 men 
(Table 1). Incidence and prevalence according to age classes are pre-
sented in Fig. 2. Prevalence of prostate cancer increased with age: 14 
cases per 100 000 were observed in men 40–49 years of age versus 14 
900 in men aged ≥90, whereas the corresponding incidence remained 
stable after 70 years of age (522, 450 and 500 cases per 100 000 in men 
aged 70–79, 80–89 and ≥90, respectively). Less than one mCRPC case 
per 100 000 was observed in men aged 40–49 versus 500 and 400 in men 
aged 80–89 and ≥90 respectively. Incidence was <1 in men aged 40–49 
and reached 175 cases per 100 000 in the 80–89-year age group, 
decreasing to 100 in men aged ≥90. Estimates were supported by a blind 
Fig. 1. Flowchart for the identification of prevalent prostate cancer, metastatic prostate cancer, castration-resistant prostate cancer (CRPC), and metastatic 
castration-resistant prostate cancer (mCRPC) cases in men covered by the general health insurance scheme, in the French national healthcare database in 2014. 
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review of the cases by experts, underlining the good performance of the 
method. Before the final adjustment of the algorithm, out of the 100 
mCRPC cases and 100 non-mCRPC cases identified by the algorithm, the 
experts agreed in 92 and 93 respectively. In total, the experts identified 
99 mCRPC and 101 non-mCRPC cases in the randomly selected pool of 
patients. At this stage, the algorithm PPV and NPV were respectively 92 
% and 99 %, after weighting. Following the final adjustment based on 
expert feedback, the updated algorithm identified 93 mCRPC and 107 
non-mCRPC cases from the same pool of patients (Table 2). Out of these, 
three were false positives (i.e. cases classified as mCRPC by the algo-
rithm and as non-mCRPC by the experts) and nine were false negatives 
(i.e. cases classified as non-mCRPC by the algorithm and as mCRPC by 
the experts). All the false-negative cases proceeded from metastatic 
hormone-sensitive patients and non-metastatic castration-resistant pa-
tients (seven and two cases respectively), although these two categories 
counted for <6% of the overall non-mCRPC cases (see Supplementary 
data, Appendix E). The resulting PPV and NPV were 97 % and 99 % 
respectively after weighting (Table 2). Based on these results, the 
sensitivity of the final algorithm was estimated as 77 % and the speci-
ficity as 100 %. 
For prevalent mCRPC patients, the initial date of diagnosis of PC 
occurred before 2010 in 70 % of the cases, although 95 % of them 
reached mCRPC status after 2010. Castration resistance and metastases 
appeared over a 4-month period in 43 % of the cases. More details about 
mCRPC patient characteristics are shown in Supplementary data, 
Appendix F. 
4. Discussion 
The present works allowed identification of mCRPC cases in the 
prostate cancer population in a large nationwide data source (the SNDS) 
through the development and validation of an ad-hoc algorithm. The 
good performances shown by the algorithm support the accuracy of the 
prevalence and incidence that we estimated for mCRPC: respectively 62 
and 21 cases per 100 000 men per year. 
The French National health insurance system (Caisse National 
d’Assurance Maladie, CNAM) estimates every year the prevalence and 
the cost associated with the main diseases supported by the general 
health insurance scheme (86 % of the French population) [13]. In 2014 
it counted 396 600 PC cases, which seems to be consistent with our 
current observation of 386 127 cases in the same population. The 
restrictive criteria used in our work (e.g. exclusion of patients potentially 
treated for paraphilia, minimum number of consecutive dispensings) 
could explain this small observed discrepancy. CAMERRA allowed the 
identification of nearly 26 500 new PC cases in 86 % of the French 
population in 2014, or approximately 33 400 at the national level. This 
number is lower than that provided in 2015 by the French network of 
cancer registries (50 430), where patients either actively treated for 
their cancer or not are tracked [11]. That may result from the 
non-inclusion of some patients having exclusively received active 
Table 1 
Prevalence and incidence of prostate cancer and metastatic castration-resistant 




Na per 100 000 menb 
(standardized, Europe) 
Prevalent prostate cancer 386 127 488 618 1 842 
Incident prostate cancer 26 470 33 364 121 
Prevalent mCRPC 12 951 16 423 62 
Incident mCRPC 4 384 5 561 21  
a Standardized on the French men age distribution (Insee), assuming the rate 
of prostate cancer as negligible in men aged <40. 
b Standardized on the European Standard Population (2013 edition), 
assuming the rate of prostate cancer as negligible in men aged <40. 
Fig. 2. Prevalence and incidence of prostate cancer and metastatic castration-resistant prostate cancer (mCRPC) according to age classes in 2014 and standardized on 
the European age distribution (2013 edition). 
Table 2 
Positive predictive values (PPV) and negative (NPV) predictive values of the 
final algorithm for the identification of metastatic castration-resistant prostate 
cancer (mCRPC) in the CAMERRA study.  
aAfter weighting. 
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surveillance (watchful waiting) as management of their prostate cancer 
over the study period, especially those without related long-term disease 
registration. However, since patients at the mCRPC stage have received 
active treatments, they should all have been included in the initial study 
population. 
At the time of the study, the general health insurance scheme 
covered wage earners in the private industrial, trade, and service sectors 
[20]. Hence included patients may present disparities in terms of 
occupation compared to the general French population. However, from 
all the ascertained risk factors for PC [21], age is the most likely to bias 
extrapolated incidence and prevalence by a differential distribution 
between the studied population and the French population. To address 
this potential issue, the number of cases at the national level were 
standardized on the 2014 French age distribution provided by the Insee. 
To facilitate potential comparisons, rates per 100 000 men per year were 
standardized on the European Standard Population (2013 edition). 
Very few data are available on mCRPC epidemiology, and to our 
knowledge no estimate relying on a large nationwide data source has 
ever been published. In 2014 Marteau et al. estimated the number of 
new mCRPC cases across eight European countries and Australia—based 
on cancer registries, literature review and medical chart review—to be 
76 201. Among these, a similar number to that observed in CAMERRA 
was approximated for France: 16 451 (versus 16 423) [22]. Further-
more, Scher et al., using a dynamic model in 2015, estimated the 
prevalence of PC and mCRPC in the US in 2009 (2.8 %) and found a ratio 
of mCRPC/PC of the same order of magnitude as that observed in 
CAMERRA (3.4 %) [23]. 
The wealth of data available in the SNDS allowed the experts to 
conduct a comprehensive blind review of cases and to reliably assess and 
validate the algorithm. Even if some medical elements are still missing, 
as in most claims databases (e.g. lab test values, imaging results, tumor, 
nodes and metastasis classification), SNDS includes exhaustive data 
about reimbursed healthcare expenditures and hospital discharge sum-
maries (drug dispensing, radiotherapy sessions, hospitalizations, pro-
cedures performed, etc.), quality of coding being ensured at the hospital 
level by specialized medical teams [24]. Data available remain rich 
enough to reconstitute electronic health records for patients, proving 
more detailed than what would usually be recorded in a standard 
medical chart. However, ruling on some cases regarding the presence or 
absence of metastases (or castration resistance) was sometimes intricate 
and open to interpretation. As highlighted by the proportion of patients 
presenting metastases and castration resistance within 4 months, the 
two stages of the disease are sometimes very close in time or even 
indistinguishable. This complexity could partially explain the sensitivity 
of the algorithm (77 %), which may induce a slight underestimation of 
the actual prevalence of mCRPC in the population. An alternative 
explanation for this imperfect sensitivity could be the absence of patient 
data prior to 2009. The limited 5year lookback period could make the 
detection of the onset of castration resistance or metastasis management 
impossible by the algorithm, especially for patients with a very long 
prostate cancer history. Furthermore, the excellent estimated specificity 
(100 %) ensures that patients identified as positive by the algorithm are 
highly likely to be true mCRPC cases and will provide a reliable study 
population for further investigation around mCRPC management. 
However, it is important to remember that as practices have substan-
tially evolved since 2016, with the introduction of new 
androgen-receptor-targeted therapies and new indications for existing 
therapies, the generation of updated results relying on SNDS data will 
require an adjustment of the algorithm [5,9,25]. 
5. Conclusion 
The good performances of the algorithm used to identify mCRPC 
cases in the SNDS, and the consistency of the generated results with the 
existing data, highlight the robustness of these first estimates of mCRPC 
prevalence and incidence in real-life settings. The accurate 
identification of this particular stage of PC in a large healthcare database 
is a first step in the evaluation of the mCRPC burden and in the assess-
ment of the evolutions of mCRPC management. 
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[10] réseau Francim, P. Grosclaude, A. Belot, L. Daubisse Marliac, L. Remontet, 
N. Leone, N. Bossard, M. Velten, [Prostate cancer incidence and mortality trends in 
France from 1980 to 2011], Prog. Urol. 25 (9) (2015) 536–542. 
[11] G. Defossez, S. Le Guyader‑Peyrou, Z. Uhry, P. Grosclaude, M. Colonna, 
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